Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$51.41 -2.2%	$46.62	$21.72 ▼ $52.85	$9.83B	1.23	2.98 million shs	2.25 million shs
BNTX BioNTech	$100.44 -1.5%	$109.79	$81.20 ▼ $131.49	$24.17B	1.23	928,064 shs	334,611 shs
INSM Insmed	$135.69 +0.5%	$110.06	$60.40 ▼ $136.90	$28.68B	0.95	2.79 million shs	1.26 million shs
ONC BeOne Medicines	$306.47 +2.9%	$283.11	$170.99 ▼ $330.63	$33.59B	0.27	424,588 shs	242,149 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+6.01%	+4.66%	+13.49%	+52.86%	+111.12%
BNTX BioNTech	-1.05%	-7.98%	-8.57%	+6.50%	+15.57%
INSM Insmed	+0.33%	+1.79%	+28.54%	+92.90%	+76.36%
ONC BeOne Medicines	-0.73%	-5.10%	-2.54%	+21.10%	+29,795,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.2331 of 5 stars	3.5	2.0	3.9	2.2	3.3	0.6
BNTX BioNTech	3.0713 of 5 stars	4.4	2.0	0.0	4.1	0.8	0.0
INSM Insmed	3.797 of 5 stars	2.5	4.0	4.3	2.8	0.8	0.6
ONC BeOne Medicines	1.4399 of 5 stars	2.5	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	3.00	Buy	$62.18	20.94% Upside
BNTX BioNTech	2.76	Moderate Buy	$135.80	35.21% Upside
INSM Insmed	2.94	Moderate Buy	$132.57	-2.30% Downside
ONC BeOne Medicines	3.00	Buy	$330.89	7.97% Upside

Current Analyst Ratings Breakdown

Latest BBIO, ONC, INSM, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/29/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $70.00
8/21/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$126.00 ➝ $144.00
8/20/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$111.00 ➝ $135.00
8/20/2025	INSM Insmed	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$138.00 ➝ $136.00
8/14/2025	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$126.00 ➝ $139.00
8/14/2025	INSM Insmed	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$121.00 ➝ $145.00
8/13/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$114.00 ➝ $142.00
8/13/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$126.00
8/13/2025	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$129.00 ➝ $148.00
8/13/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $165.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$235.81M	41.68	N/A	N/A	($9.30) per share	-5.53
BNTX BioNTech	$2.88B	8.39	N/A	N/A	$87.38 per share	1.15
INSM Insmed	$363.71M	78.86	N/A	N/A	$5.91 per share	22.96
ONC BeOne Medicines	$4.56B	7.36	N/A	N/A	$34.40 per share	8.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$4.09	N/A	N/A	N/A	-329.25%	N/A	-85.69%	11/11/2025 (Estimated)
BNTX BioNTech	-$719.92M	-$1.60	N/A	N/A	N/A	-12.20%	-1.84%	-1.59%	11/3/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.71	N/A	N/A	N/A	-259.82%	-195.37%	-49.49%	10/30/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	431.65	N/A	-3.89%	-1.22%	-0.72%	N/A

Latest BBIO, ONC, INSM, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	INSM Insmed	-$1.30	-$1.70	-$0.40	-$1.70	$104.06 million	$107.42 million
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion
8/5/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.83	-$0.95	-$0.12	-$0.95	$98.46 million	$110.57 million
8/4/2025	Q2 2025	BNTX BioNTech	-$1.41	-$1.60	-$0.19	-$1.82	$161.26 million	$306.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.52%	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	5.19	5.08
BNTX BioNTech	0.01	8.61	8.48
INSM Insmed	0.45	6.68	6.33
ONC BeOne Medicines	0.04	1.95	1.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BNTX BioNTech	15.52%
INSM Insmed	N/A
ONC BeOne Medicines	48.55%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BNTX BioNTech	19.20%
INSM Insmed	3.00%
ONC BeOne Medicines	6.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	191.17 million	156.38 million	Optionable
BNTX BioNTech	3,080	240.40 million	194.24 million	Optionable
INSM Insmed	740	211.38 million	205.03 million	Optionable
ONC BeOne Medicines	9,000	109.60 million	102.34 million	N/A

BBIO, ONC, INSM, and BNTX Headlines

Recent News About These Companies

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

August 29 at 6:00 AM | businesswire.com $https://www.businesswire.com/news/home/20250829435188/en/beone-medicines-announces-positive-topline-results-for-sonrotoclax-in-relapsed-or-refractory-mantle-cell-lymphoma-mcl/$

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of "Buy" from Analysts

August 29 at 3:32 AM | marketbeat.com

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives Average Rating of "Buy" from Analysts

August 29 at 3:32 AM | marketbeat.com

BeOne Medicines announces EC approved Tevimbra to treat NSCLC

August 28 at 10:46 PM | msn.com

With 42% institutional ownership, BeOne Medicines Ltd. (NASDAQ:ONC) is a favorite amongst the big guns

August 28 at 12:45 PM | finance.yahoo.com

BeOne Medicines shares dip after EU greenlights TEVIMBRA for lung cancer

August 27 at 12:27 AM | msn.com

BeOne Meds sells Imdelltra royalty for up to $950 million

August 26 at 4:01 PM | thepharmaletter.comT

EC approves tablet formulation of BeOne Medicines’ Brukinsa

August 26 at 6:53 AM | thepharmaletter.comT

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 26 at 6:01 AM | businesswire.com

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

August 25, 2025 | finance.yahoo.com

BeOne Medicines Announces $950 Million Royalty Purchase Agreement with Royalty Pharma for Imdelltra

August 25, 2025 | pharmexec.comP

Royalty Pharma confirms acquisition of royalty interest in Amgen’s Imdelltra

August 25, 2025 | msn.com

BeOne bags $885M upfront in Royalty deal on Amgen's lung cancer drug Imdelltra

August 25, 2025 | fiercepharma.comF

BeOne Medicines to sell royalty rights of Imdelltra to Royalty Pharma for $950M

August 25, 2025 | msn.com

BeOne Medicines’ new film-coated tablet formulation of Brukinsa gets European nod for all approved indications

August 23, 2025 | pharmabiz.comP

BRUKINSA Tablet Approval Could Be a Game Changer for BeOne Medicines (ONC)

August 22, 2025 | finance.yahoo.com

BeOne Medicines’ Brukinsa tablet formulation approved by European Commission

August 21, 2025 | msn.com

European Commission Approves Tablet Formulation of BeOne Medicines' BRUKINSAÂ® for All Approved Indications

August 21, 2025 | businesswire.com

Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) COO Sells 39,936 Shares of Stock

August 18, 2025 | americanbankingnews.com

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Sells $3,308,855.85 in Stock

August 17, 2025 | marketbeat.com

Xiaobin Wu Sells 39,936 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock

August 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BBIO, ONC, INSM, and BNTX Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$51.41 -1.16 (-2.20%)

As of 03:54 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BioNTech NASDAQ:BNTX

$100.44 -1.50 (-1.47%)

As of 03:54 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Insmed NASDAQ:INSM

$135.69 +0.72 (+0.53%)

As of 03:54 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

BeOne Medicines NASDAQ:ONC

$306.47 +8.51 (+2.86%)

As of 03:33 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time